LB
Laigo Bio
Netherlands · Biotech
Laigo Bio develops targeted protein degradation therapies for cancer and autoimmune diseases.
Product
Laigo Bio is a Utrecht biotechnology company developing therapies that remove disease-driving proteins from cell surfaces. Its SureTACs platform creates bispecific antibodies that bring a target protein into contact with an E3 ligase, triggering its internalisation and degradation.
The company applies this approach to oncology, autoimmune disease and graft rejection. Its programmes build on research involving UMC Utrecht and the Oncode Institute, with the aim of advancing drug candidates towards clinical development.
Funding history
3 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed second close | €5.5M | Biovance Capital — LeadKurma Partners — Lead | |
| Seed first close | €11.5M | Curie Capital — LeadKurma Partners — LeadAngelini Ventures — ParticipantArgobio Studio — ParticipantCancer Research Horizons — ParticipantEurazeo — ParticipantOncode Bridge Fund — ParticipantROM Utrecht Region — Participant | |
| TKI-MKB research grant | Undisclosed | Health~Holland — Participant |
Investors
Biovance CapitalLed Seed second closeKurma PartnersLed Seed second close · Led Seed first closeCurie CapitalLed Seed first closeAngelini VenturesJoined Seed first closeArgobio StudioJoined Seed first closeCancer Research HorizonsJoined Seed first closeEurazeoJoined Seed first closeOncode Bridge FundJoined Seed first closeROM Utrecht RegionJoined Seed first closeHealth~HollandJoined TKI-MKB research grantCoverage
Mar 23, 2026Laigo Bio · Seed second closeDec 4, 2025Laigo Bio · Seed first closeOct 15, 2024Laigo Bio · TKI-MKB research grantSimilar companies
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A
OOOrakl OncologyCombines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.$34M · Series A